P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles

Схожі ресурси

• P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
  за авторством: Chiara Rusconi, та інші
  Опубліковано: (2022-10-01)
• Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma
  за авторством: Armando Santoro, та інші
  Опубліковано: (2020-01-01)
• Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope
  за авторством: Lisa Argnani, та інші
  Опубліковано: (2025-03-01)
• P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
  за авторством: Chiara Rusconi, та інші
  Опубліковано: (2022-10-01)
• P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.
  за авторством: Ya.K. Mangasarova, та інші
  Опубліковано: (2022-10-01)